Skip to content
MarketScale
‹ Back to IndustriesSciences

Minerals and Gravity Gradiometry – The Whole World in Your Hands

Gravity gradiometry is a crucial technique for mineral exploration in the oil and gas industry. This method measures variations in gravity which helps in identifying mineral deposits. Experts Dr. Tim Wright and Gaud Pouliquen discuss its significance and applications.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · DensityFull Tensor GradiometryGravity GradiometryMagnetism
Share

Key takeaways

01

Gravity gradiometry measures variations in gravity for mineral exploration.

02

It is essential for oil, gas, and mining industries.

03

Experts Tim Wright and Gaud Pouliquen provided insights into its applications.

Gravity and density are both critical to mineral explorers. The art of measuring variations in it, called gravity gradiometry, is of key importance to the oil and gas and mining industries.

To glean some expert insights, A Propensity to Talk Density host Tyler Kern spoke with experts Dr. Tim Wright, Director and Principal Geoscientist at Scorpion Geoscience Ltd, and Gaud Pouliquen, Business Development Manager EAMEAA at Bell Geospace.

Dr. Wright first explained the connection between gravity and density. “It’s a fundamental force of nature that every object experiences. Density and gravity are related,” Wright said. “Density affects gravity, and gravity is a measure of density. We can use that to our advantage in exploring.”

Gravity and density help identify rocks and materials because of the contrast. “These changes are measurable with a gravity gradiometer. It measures the rate of change of gravitational acceleration due to underlying rock properties. It’s the second most accurate instrument after the atomic clock” Pouliquen said.

The detected contrasts can be due to a change in density or a change in geometry. Much of the time, the contrasts indicate the rocks and materials that the oil and gas and mining industries seek to discover.

Wright also explained the basics of rocks and minerals.“ Rocks are often described by colors and textures. The rocks we are looking for are harder to find but have characteristics we can detect,” Wright said. “There’s a density spectrum.” Next, he shared samples of a variety of rocks and their attributes.

Full Tensor Gravity Gradiometry (FTG) is even more exact in finding anomalies, as it measures the full gravity field in all directions.

“With this 3D gradiometry, we can use magnetism and gravity to determine different physical properties,” Pouliquen added.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

S
Sciences

Host, A Propensity to Talk Density

Tyler Kern is the host of the podcast series A Propensity to Talk Density, where he explores scientific topics with industry experts.

DT
Dr. Tim Wright

Director and Principal Geoscientist

Scorpion Geoscience Ltd

Dr. Tim Wright is an experienced geoscientist specializing in gravity gradiometry. He is the Director and Principal Geoscientist at Scorpion Geoscience Ltd.

GP
Gaud Pouliquen

Business Development Manager EAMEAA

Bell Geospace

Gaud Pouliquen is the Business Development Manager for the EAMEAA region at Bell Geospace. He focuses on advancing geophysical technologies in the mining and oil sectors.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512